AI Article Synopsis

  • Ocular myasthenia gravis (OMG) frequently progresses to generalized myasthenia gravis within two years of symptom onset, prompting this study to identify risk factors in patients not receiving immunosuppression or thymectomy treatment.
  • The researchers analyzed clinical data from 572 OMG patients across seven hospitals in China, focusing on various characteristics including age, symptoms, and antibody presence to determine factors influencing generalization of the disease.
  • Findings indicated that early and late onset in adulthood, abnormal repetitive nerve stimulation results, positive anti-acetylcholine receptor antibodies, and the presence of thymoma significantly increased the risk of disease generalization among these patients.

Article Abstract

Introduction: Many patients with ocular myasthenia gravis (OMG) progress to generalized disease within the first 2 years of the onset of ocular symptoms. Several retrospective studies have identified risk factors associated with generalization, however these studies included patients on immunosuppression therapy or those undergoing thymectomy, which may reduce the generalization risk. In this study we explored the risk factors for generalization in non-immunosuppressed and non-thymectomized patients with OMG.

Methods: Data from patients with OMG treated at seven tertiary hospitals in China were retrospectively reviewed. Clinical characteristics, including sex, age at onset, symptoms at onset, comorbid autoimmune diseases, neostigmine test response, repetitive nerve stimulation (RNS) findings, presence of serum anti-acetylcholine receptor antibody (AChR-Ab), and thymic status based on radiological and pathological studies, were collected. The main outcome measure was disease generalization. The follow-up period was defined as the date of ocular symptom onset to the date of confirmation of generalization or immunotherapy initiation, or last follow-up (defined as 60 months). The Cox proportional hazards model was used to assess the risk factors for generalization.

Results: Overall, 572 patients (269 women) were eligible for inclusion in the analysis, of whom 144 developed generalization. The mean (standard deviation) onset age was 45.5 (19.8) years, and the median (interquartile range) follow-up period was 14.5 (7.0-47.3) months. Multivariable Cox regression analysis demonstrated that both early-onset (adjusted hazard ratio [aHR] 5.34; 95% confidence interval [CI] 1.64-17.36; p = 0.005) and late-onset (aHR 7.18; 95% CI 2.22-23.27; p = 0.001) in adulthood, abnormal RNS findings (aHR 3.01; 95% CI 1.97-4.61; p < 0.001), seropositivity for AChR-Ab (aHR 2.58; 95% CI 1.26-5.26; p = 0.01), and thymoma (aHR 1.62; 95% CI 1.05-2.49; p = 0.03) were independently associated with increased risk of generalization.

Conclusion: The risk of generalization increased significantly in patients with adult-onset OMG, abnormal RNS findings, seropositivity for AChR-Ab, and thymoma, suggesting that these risk factors may predict OMG generalization.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857387PMC
http://dx.doi.org/10.1007/s40120-021-00292-xDOI Listing

Publication Analysis

Top Keywords

risk factors
16
factors generalization
8
patients ocular
8
ocular myasthenia
8
myasthenia gravis
8
rns findings
8
follow-up period
8
generalization
7
patients
6
risk
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!